{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:22:15Z","timestamp":1793830935491,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["24SF1901304"],"award-info":[{"award-number":["24SF1901304"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Municipal Health Bureau Project","award":["202340195"],"award-info":[{"award-number":["202340195"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03941-9","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T14:53:35Z","timestamp":1753368815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Successful treatment of advanced Birt-Hogg-Dub\u00e9 syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report"],"prefix":"10.1186","volume":"23","author":[{"given":"Liqi","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"3941_CR1","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S1470-2045(09)70188-3","volume":"10","author":"FH Menko","year":"2009","unstructured":"Menko FH, Van Steensel MA, Giraud S, Friis-Hansen L, Richard S, Ungari S, et al. Birt-Hogg-Dub\u00e9 syndrome: diagnosis and management. Lancet Oncol. 2009;10:1199\u2013206.","journal-title":"Lancet Oncol"},{"key":"3941_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.semdp.2024.01.008","volume":"41","author":"J Wu","year":"2024","unstructured":"Wu J, Lu J, Wu C-L, Lu M. Birt-Hogg-Dub\u00e9 syndrome in an overall view: focus on the clinicopathological prospects in renal tumors. Semin Diagn Pathol. 2024;41:119\u201324.","journal-title":"Semin Diagn Pathol"},{"key":"3941_CR3","doi-asserted-by":"publisher","first-page":"e16877","DOI":"10.15252\/emmm.202216877","volume":"15","author":"C Di Malta","year":"2023","unstructured":"Di Malta C, Zampelli A, Granieri L, Vilardo C, De Cegli R, Cinque L, et al. TFEB and TFE3 drive kidney cystogenesis and tumorigenesis. EMBO Mol Med. 2023;15:e16877.","journal-title":"EMBO Mol Med"},{"key":"3941_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/PAS.0000000000002152","volume":"48","author":"X-M Wang","year":"2024","unstructured":"Wang X-M, Mannan R, Zhang Y, Chinnaiyan A, Rangaswamy R, Chugh S, et al. Hybrid oncocytic tumors (HOTs) in Birt-Hogg-Dub\u00e9 syndrome Patients-A Tale of two cities: sequencing analysis reveals dual lineage markers capturing the 2 cellular populations of HOT. Am J Surg Pathol. 2024;48:163\u201373.","journal-title":"Am J Surg Pathol"},{"key":"3941_CR5","doi-asserted-by":"publisher","first-page":"100396","DOI":"10.1016\/j.modpat.2023.100396","volume":"37","author":"K Collins","year":"2024","unstructured":"Collins K, Acosta AM, Siegmund SE, Cheng L, Hirsch MS, Idrees MT. Genetic profiling uncovers Genome-Wide loss of heterozygosity and provides insight into mechanisms of sarcomatoid transformation in chromophobe renal cell carcinoma. Mod Pathol. 2024;37:100396.","journal-title":"Mod Pathol"},{"key":"3941_CR6","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1097\/PAS.0000000000002233","volume":"48","author":"AJ Adeniran","year":"2024","unstructured":"Adeniran AJ, Shuch B, Humphrey PA. Sarcomatoid and rhabdoid renal cell carcinoma: clinical, pathologic, and molecular genetic features. Am J Surg Pathol. 2024;48:e65\u201388.","journal-title":"Am J Surg Pathol"},{"key":"3941_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","volume":"17","author":"KA Blum","year":"2020","unstructured":"Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, et al. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol. 2020;17:659\u201378.","journal-title":"Nat Rev Urol"},{"key":"3941_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00345-018-2355-y","volume":"37","author":"C Lebacle","year":"2019","unstructured":"Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the Art. World J Urol. 2019;37:115\u201323.","journal-title":"World J Urol"},{"key":"3941_CR9","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/j.clgc.2019.01.005","volume":"17","author":"M Alevizakos","year":"2019","unstructured":"Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid renal cell carcinoma: Population-Based study of 879 patients. Clin Genitourin Cancer. 2019;17:e447\u201353.","journal-title":"Clin Genitourin Cancer"},{"key":"3941_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.asjsur.2023.06.065","volume":"47","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Shi Z, Xie Y, Li N, Chen H, Jin M. The association between PD-1 \/ PD-L1 expression and clinicopathological features in sarcomatoid renal cell carcinoma. Asian J Surg. 2024;47:163\u20138.","journal-title":"Asian J Surg"},{"key":"3941_CR11","doi-asserted-by":"publisher","first-page":"104909","DOI":"10.1016\/j.yexmp.2024.104909","volume":"138","author":"T \u010cugura","year":"2024","unstructured":"\u010cugura T, Bo\u0161tjan\u010di\u010d E, Uhan S, Hauptman N, Jeruc J. Epithelial-mesenchymal transition associated markers in sarcomatoid transformation of clear cell renal cell carcinoma. Exp Mol Pathol. 2024;138:104909.","journal-title":"Exp Mol Pathol"},{"key":"3941_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","volume":"3","author":"RW Joseph","year":"2015","unstructured":"Joseph RW, Millis SZ, Carballido EM, Bryant D, Gatalica Z, Reddy S, et al. PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation. Cancer Immunol Res. 2015;3:1303\u20137.","journal-title":"Cancer Immunol Res"},{"key":"3941_CR13","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1159\/000534000","volume":"16","author":"J Ell","year":"2023","unstructured":"Ell J, Balz P, Manava P, H\u00fcttenbrink C. Downstaging and pathological complete response of locally recurrent sarcomatoid renal cell carcinoma under pembrolizumab and lenvatinib: A case report and review of literature. Case Rep Oncol. 2023;16:1245\u201352.","journal-title":"Case Rep Oncol"},{"key":"3941_CR14","unstructured":"Comparison of tyrosine. kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations - PubMed. [cited 2025 Apr 29]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/37325945\/"},{"key":"3941_CR15","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/ijc.35141","volume":"155","author":"C Ciccarese","year":"2024","unstructured":"Ciccarese C, B\u00fcttner T, Cerbone L, Zampiva I, Monteiro FSM, Basso U, et al. Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de-differentiation (ARON-1 study). Int J Cancer. 2024;155:2036\u201346.","journal-title":"Int J Cancer"},{"key":"3941_CR16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-023-10754-0","volume":"23","author":"H Lu","year":"2023","unstructured":"Lu H, Ye Q, Zheng C, Fan L, Xia X. Efficacy and safety analysis of TACE\u2009+\u2009sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study. BMC Cancer. 2023;23:270.","journal-title":"BMC Cancer"},{"key":"3941_CR17","doi-asserted-by":"publisher","first-page":"5873","DOI":"10.3390\/cancers15245873","volume":"15","author":"K Bekku","year":"2023","unstructured":"Bekku K, Kawada T, Sekito T, Yoshinaga K, Maruyama Y, Yamanoi T, et al. The diagnosis and treatment approach for Oligo-Recurrent and Oligo-Progressive renal cell carcinoma. Cancers (Basel). 2023;15:5873.","journal-title":"Cancers (Basel)"},{"key":"3941_CR18","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","volume":"24","author":"Y-W Chen","year":"2023","unstructured":"Chen Y-W, Wang L, Panian J, Dhanji S, Derweesh I, Rose B, et al. Treatment landscape of renal cell carcinoma. Curr Treat Options Oncol. 2023;24:1889\u2013916.","journal-title":"Curr Treat Options Oncol"},{"key":"3941_CR19","doi-asserted-by":"publisher","first-page":"102585","DOI":"10.1016\/j.eclinm.2024.102585","volume":"71","author":"Y Liang","year":"2024","unstructured":"Liang Y, Liu J, Ge J, Shi Q, Zhang G, Wan A, et al. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II\/III triple-negative breast cancer in China (the NeoALTAL trial): a single-arm, phase 2 trial. eClinicalMedicine. 2024;71:102585.","journal-title":"eClinicalMedicine"},{"key":"3941_CR20","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.2147\/DDDT.S426898","volume":"17","author":"S Li","year":"2023","unstructured":"Li S, Wang H. Research progress on mechanism and management of adverse drug reactions of anlotinib. Drug Des Devel Ther. 2023;17:3429\u201337.","journal-title":"Drug Des Devel Ther"},{"key":"3941_CR21","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s43440-025-00700-1","volume":"77","author":"G Wang","year":"2025","unstructured":"Wang G, Wang Y, Jin C, Sun X. Off-label use of anlotinib in malignancies\u2019 treatment: efficacy and management of adverse reactions. Pharmacol Rep. 2025;77:392\u2013408.","journal-title":"Pharmacol Rep"},{"key":"3941_CR22","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1634\/theoncologist.2018-0839","volume":"24","author":"A-P Zhou","year":"2019","unstructured":"Zhou A-P, Bai Y, Song Y, Luo H, Ren X-B, Wang X, et al. Anlotinib versus Sunitinib as First-Line treatment for metastatic renal cell carcinoma: A randomized phase II clinical trial. Oncologist. 2019;24:e702\u20138.","journal-title":"Oncologist"},{"key":"3941_CR23","doi-asserted-by":"publisher","first-page":"e0281402","DOI":"10.1371\/journal.pone.0281402","volume":"18","author":"J Lin","year":"2023","unstructured":"Lin J, Fang Q, Zheng X. Cost-effectiveness analysis of anlotinib versus Sunitinib as first-line treatment for metastatic renal cell carcinoma in China. PLoS ONE. 2023;18:e0281402.","journal-title":"PLoS ONE"},{"key":"3941_CR24","doi-asserted-by":"publisher","first-page":"113197","DOI":"10.1016\/j.yexcr.2022.113197","volume":"417","author":"J Li","year":"2022","unstructured":"Li J, Cao P, Chen Y, Wang J, Sun X, Chen R, et al. Anlotinib combined with the PD-L1 Blockade exerts the potent anti-tumor immunity in renal cancer treatment. Exp Cell Res. 2022;417:113197.","journal-title":"Exp Cell Res"},{"key":"3941_CR25","doi-asserted-by":"crossref","unstructured":"Kwon JW, Natcher PL, Antic T. Aggressive renal cell carcinoma with somatic BRCA2 mutation-an emerging entity? A case report with literature review. Virchows Arch. 2024.","DOI":"10.1007\/s00428-024-04008-y"},{"key":"3941_CR26","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.3390\/cancers15082357","volume":"15","author":"SSY Wang","year":"2023","unstructured":"Wang SSY, Jie YE, Cheng SW, Ling GL, Ming HVY. PARP inhibitors in breast and ovarian Cancer. Cancers (Basel). 2023;15:2357.","journal-title":"Cancers (Basel)"},{"key":"3941_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s40265-022-01703-5","volume":"82","author":"R Flippot","year":"2022","unstructured":"Flippot R, Patrikidou A, Aldea M, Colomba E, Lavaud P, Albig\u00e8s L, et al. PARP inhibition, a new therapeutic avenue in patients with prostate Cancer. Drugs. 2022;82:719\u201333.","journal-title":"Drugs"},{"key":"3941_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","volume":"19","author":"H Zhu","year":"2020","unstructured":"Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19:49.","journal-title":"Mol Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03941-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03941-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T21:30:40Z","timestamp":1757280640000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03941-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3941"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03941-9","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical specimens were obtained under the approval of the Institutional Ethics Committee. Informed consent was obtained from the subject. Research involving human subjects, human material, or human data, have been performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the consent form is available for review by the editor of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}